Axcelead is Japan's first provider of integrated drug discovery services

We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda Pharmaceutical Company Limited (“Takeda”) as a core company of “Drug Discovery Gateway Investment Limited Partnership” (“DDG Fund”). Under the terms of the agreement between Takeda and Japan-based Alternative Asset Management Firm, Whiz Partners, Inc. (“Whiz”), DDG Fund will be established by Whiz, and will be launched in November 2018. Takeda will invest Axcelead, in kind into the DDG Fund at the timing of DDG Fund's launch, and Axcelead will be affiliated with go under the umbrella of DDG Fund.

We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred to as “Axcelead”) and Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Consultants BV (Henk-Jan Drenth, Managing Director; Headquarters: Leiden, the Netherlands; hereinafter referred to as “LAP&P”) decided to develop a business partnership for services provided by Axcelead, in the field of pharmacokinetic and pharmacodynamic analyses (hereinafter referred to as “PK/PD analyses”) and modeling and simulation (hereinafter referred to as “M&S”). We great appreciate that total hundreds of visitors dropped by our booth.

Takeda Pharmaceutical Company Limited [TSE: 4502] (Headquarters: Osaka, Japan; "Takeda") and Axcelead Drug Discovery Partners, Inc. (Headquarters: Kanagawa, Japan; former name: "PRE Business preparation Company," "AXCELEAD") announced the start of operations for AXCELEAD occurred on July 1, 2017. AXCELEAD is the receiving company to which Takeda...